Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Peptide-anchored neutrophil membrane-coated biomimetic nanodrug for targeted treatment of rheumatoid arthritis

Fig. 5

Effects of R4F-NM@F127-Cel on LPS-induced RAW264.7 cells polarization in vitro. a iNOS and Arg-1 protein expression in LPS-treated RAW264.7 cells after different treatments, as evaluated by western blot assay. b–c MFI of CD86 and CD206 on LPS-treated RAW264.7 cells by flow cytometry. MFI: mean fluorescence intensity. d–f ELISA results for TNF-α (d), IL-6 (e) and IL-10 (f) secretion in LPS-treated RAW264.7 cells supernatants from various treatment groups. g Effects of different treatments on the expression levels of components of the NF-κB pathway, including total p65, p-p65, IκBα, p-IκBα, cytoplasmic p65 and nuclear p65, as determined by western blotting. h–i Quantitative analysis of p-p65/p65 and p-IκBα/IκBα protein levels. j Confocal fluorescence images of p65 nuclear localization. Scale bar, 5 μm; Blue, DAPI; Red, p65. k Effects of different treatments on the expression levels of compontents of MAPK pathway, including JNK, p-JNK, ERK and p-ERK, as determined by western blotting. l–m Quantitative analysis of p-JNK/JNK and p-ERK/ERK protein levels. Data are presented as the mean ± SEM (n = 3) and were statistically analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test by comparing the group marked with * with the LPS group. ns represents no significant difference. *p < 0.05, **p < 0.01, ***p < 0.001; #p < 0.05, ##p < 0.01 and ###p < 0.001

Back to article page